Folks, Canopy has released a presser but not published fins. If they publish after hours I should have something more formal up by Monday at noon.
But I figured you would want some notes:
Growth in International cannabis revenue by $4.2 million or 22%.
Yoinked aEBITDA guidance. We had this pegged on March 31, 2021 figures.
Sales decreased 3.5% QoQ. Each segment except International Cannabis sales, decreased.
B2B Adult use sales, net of $14 million from Supreme and Ace acquisitions, is lowest on record. Like, since adult use was launched.
$14 million in Supreme and Ace revenue would equal Supreme ONLY revenue in March 31, 2021 Q.
Gross Margin gets an $87 million impairment and rings in at negative 54%. Without impairment and step-up GM is 14%.
How they will get to 30% let alone 40% GM when Other Revenue has a 32% GM and B2C (Retail) is likely sub 30% is a work of fiction. They need cannabis GM, which is presently 8% without impairment and step-ups, to exceed 40% when their best adjusted GM on cannabis is 22% over past 6 Qs.
Other Financial Assets decrease $282 million to $509 million as stock prices fall in their portfolio companies.
This dog won’t hunt.
The preceding is the opinion of the author and is in no way intended to be a recommendation to buy or sell any security or derivative. The author does not have a position in CGC and will not start one in the next five days.
Ads Blocker Detected!!!
We have detected that you are using extensions to block ads. Please support us by disabling your ad blocker.